EN DE
Watch Zhejiang Sunflower Light Energy for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Zhejiang Sunflower Light Energy (300111) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Zhejiang Sunflower Light Energy stock ¥0.57, price ¥3.29, that is 82.7% below the price, quality 40 out of 100. Rating: strongly overvalued. Calculated from audited financials with 2 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare CN · ISIN CNE100000SX9

ZS Zhejiang Sunflower Light Energy logo Thin data Nov 7, 2026

Zhejiang Sunflower Light Energy

300111 · SHE
Very expensive, weak quality

Our calculation puts a fair price 83% below what the stock costs today.

Low debt
Quality 40/100
Revenue last quarter 25% below a year ago.
Fair value ¥0.5700 · Strongly overvalued (−82.7%)
Weak Growth (revenue 5y −1.1 %/yr in CNY)
Loss-making · -7.6% net margin (TTM)
Negative free cash flow
Trails peers (0/10)
Narrow moat 14/100 · thin data
Thin data
Watch Zhejiang Sunflower Light Energy for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

¥9.43 ¥1.87 Fair Value ¥0.5700 May 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.

How to read this chart

60‑month range ¥1.87 – ¥9.43 · fair‑value band ¥0.5400 – ¥0.6000 · the ¥3.29 price screens above the ¥0.5700 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 7, 2026.

Follow Zhejiang Sunflower Light Energy in your weekly email

Every Wednesday you see whether Zhejiang Sunflower Light Energy is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Zhejiang Sunflower Great Health Co., Ltd. engages in the research, development, production, and sale of anti-infectious, cardiovascular, digestive system and other drugs in China and internationally.

Show moreShow less

It offers clarithromycin API and tablets, anti-infective drugs used for nasopharyngeal infection, lower respiratory tract infection, skin and soft tissue infection, acute otitis media, Mycoplasma pneumonia, and urethritis and cervicitis; and azithromycin dispersible tablets and injections for sinusitis, acute otitis media, acute bronchitis, acute exacerbation of chronic bronchitis, streptococcus pneumoniae, pneumonia, haemophilus influenzae, mycoplasma pneumoniae, urethritis, cervicitis and skin and soft tissue infection.

The company also provides roxithromycin capsules to treat pharyngitis and tonsillitis caused by Streptococcus pyogenes, sinusitis, otitis media, acute bronchitis, acute exacerbation, as well as urethritis, cervicitis, and skin and soft tissue infection.

In addition, it offers lacidipine dispersible tablets for the treatment of high blood pressure; and simvastatin tablets used for hyperlipidemia, coronary heart disease combined with hypercholesterolemia, and children with heterozygous familial hypercholesterolemia.

Further, the company provides omeprazole sodium for injection, a digestive system drug, used as an alternative therapy for duodenal ulcer, gastric ulcer, reflux esophagitis, and Zollinger-Ellison syndrome; and famotidine for injection for treatment of peptic ulcer bleeding, acute gastric mucosal damage, and gastrointestinal bleeding caused by non-steroidal anti-inflammatory drugs.

The company was formerly known as Zhejiang Sunflower Great Health Limited Liability Company and changed its name to Zhejiang Sunflower Great Health Co., Ltd. in December 2023. Zhejiang Sunflower Great Health Co., Ltd. was founded in 2005 and is headquartered in Shaoxing, China.

Stock analysis

Zhejiang Sunflower Light Energy (300111) currently trades at ¥3.29, while our model-based Fair Value estimate is ¥0.5700, 83% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 2 models at a data quality of 80/100, which puts the data coverage at low.

Scenario range: ¥0.5400 (bear) to ¥0.6000 (bull), the price of ¥3.29 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Zhejiang Sunflower Light Energy reported revenue of 272M CNY in FY2025 versus 297M CNY in FY2021, a compound −2.2%/yr. Reported net income was −4.4M CNY in FY2025.

Key figures

Market cap 4.2B CNY (≈ $635M) Small · P/S ratio 17.1 · EPS (TTM) ¥−0.0100 · Net margin −1.6% · Return on equity −2.1% · Return on assets (EBIT) 2.5% (5-year average) · Operating margin 1.2% · Revenue (TTM) 236M CNY.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 14 out of 100 (low confidence).

What moves the price

The share trades about 61% below its 52-week high and 26% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −83%, 300111 screens richer than that median.

Fair Value models

Bear ¥0.5400 Fair Value ¥0.5700 Bull ¥0.6000
Price ¥3.29 · Downside -82.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
EV/EBITDA ¥0.5400 ¥0.5700 ¥0.6000 67
NCAV (Graham) ¥0.2500 ¥0.3800 ¥0.4700 55
All 2 models by family
Multiples
EV/EBITDA ¥0.5400 ¥0.5700 ¥0.6000 67
Asset-Based
NCAV (Graham) ¥0.2500 ¥0.3800 ¥0.4700 55

Open the full fair value analysis →

Quality Score breakdown

Overall quality 40/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 12
How much profit the company makes from its sales and capital
Quality Growth 19
Are margins and returns getting better?
Cashflow 10
Do the profits arrive as real cash?
Financial strength 98
Debt, balance sheet and risk of trouble
Investment 36
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 29
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 5
Distance to the 52-week high, does not count
New shares 67
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 2/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−17.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−6.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.1%
Start year 2020 (pandemic). Over 10 years: −17.3% a year
Revenue growth 18 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
25.7% (2020) → −2.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

300111 screens overvalued: fair value 83% below the price. Compare with Merck KGaA →

Compare Zhejiang Sunflower Light Energy with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks

Beats the industry median on 0/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 40 · Bottom 25%
Fair Value upside −82.7% · Bottom 25%
Profitability
Return on assets −0.5% · Bottom 25%
Net margin (12 months) −7.6% · Bottom 25%
Operating margin (12 months) 1.2% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −25.2% · Bottom 25%
Balance sheet
Debt / equity 0.18× · Above median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 6.21× · Priciest 25%
P/S (12 months) 17.97× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 15
FUTURE (revenue growth)0 · sector 25
PAST (return on equity)0 · sector 29
HEALTH (low debt)91 · sector 96
DIVIDEND (yield)0 · sector 32

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $79.40 $111.63 +41% vs 300111
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥50.43 ¥55.21 +9% vs 300111
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,860 ₹1,947 +5% vs 300111
Haleon plc HLN $9.14 $8.61 −6% vs 300111
Merck KGaA MRK €148.75 €109.18 −27% vs 300111
Galderma Group GALD CHF 191.75 CHF 109.86 −43% vs 300111
Takeda Pharmaceutical Company TAK $21.02 $11.31 −46% vs 300111
Teva Pharmaceutical Industries Limited TEVA $42.61 $20.74 −51% vs 300111
Sandoz Group SDZ CHF 83.78 CHF 39.70 −53% vs 300111
Divi's Laboratories Limited DIVISLAB ₹10,321 ₹1,567 −85% vs 300111

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Zhejiang Sunflower Light Energy: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Zhejiang Sunflower Light Energy Fair Value". https://www.fairvalue-calculator.com/stock/300111

Frequently asked questions

Is Zhejiang Sunflower Light Energy (300111) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of ¥0.5700 versus a price of ¥3.29, about 83% lower (overvalued).
What is the fair value of 300111?
Our model-based fair value for Zhejiang Sunflower Light Energy is ¥0.5700 (as of Nov 7, 2026), built from audited fundamentals. The current price: ¥3.29.
What is the quality score of 300111?
Zhejiang Sunflower Light Energy has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Zhejiang Sunflower Light Energy (300111)?
Our model-based price target is the fair value of ¥0.5700 (as of Nov 7, 2026) from 2 valuation models. Cautious scenario ¥0.5400, optimistic scenario ¥0.6000. It is a calculation from audited fundamentals, not an analyst target.
What is the Zhejiang Sunflower Light Energy stock forecast for 2026?
Our models put fair value at ¥0.5700, about 83% lower versus a price of ¥3.29 (overvalued). Cautious scenario ¥0.5400, optimistic scenario ¥0.6000. The calculation is refreshed regularly with new filings.
What is the revenue of Zhejiang Sunflower Light Energy (300111)?
Zhejiang Sunflower Light Energy reported trailing-twelve-month revenue of about 236M CNY (latest available figure, as of Nov 7, 2026).
What is the intrinsic value of Zhejiang Sunflower Light Energy (300111)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Zhejiang Sunflower Light Energy it is ¥0.5700 per share (as of Nov 7, 2026), against a price of ¥3.29. It is the blended result of 2 valuation models in 2 families (Multiples, Asset-Based).
Is Zhejiang Sunflower Light Energy stock overvalued or undervalued in 2026?
As of Nov 7, 2026, 300111 trades above its calculated fair value: price ¥3.29, fair value ¥0.5700, a gap of about −83% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 300111?
No. The price is what the market pays today (¥3.29); the fair value is what the company's own numbers justify (¥0.5700). For Zhejiang Sunflower Light Energy the two are ¥2.72 per share apart. That gap is exactly why we show both numbers side by side.
How much is Zhejiang Sunflower Light Energy worth?
The market values Zhejiang Sunflower Light Energy at about 4.2B CNY (market capitalisation, as of Nov 7, 2026). Per share that is ¥3.29; our models calculate a fair value of ¥0.5700 per share.
What do the bullish and bearish scenarios say about 300111?
Our models span a range for Zhejiang Sunflower Light Energy: cautious scenario ¥0.5400, base ¥0.5700, optimistic ¥0.6000 per share (as of Nov 7, 2026, price ¥3.29). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Zhejiang Sunflower Light Energy (300111)?
Balance-sheet figures for Zhejiang Sunflower Light Energy (as of Nov 7, 2026): return on equity −2.1%, debt of 0.18 per unit of equity. They feed the Quality Score of 40/100, which measures business quality independently of the share price.
How far is 300111 from its 52-week high?
Zhejiang Sunflower Light Energy trades at ¥3.29, about 61% below its 52-week high of ¥8.41 and 26% above the low of ¥2.61 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of ¥0.5700 is for.
Which stocks are comparable to Zhejiang Sunflower Light Energy?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Zhejiang Sunflower Light Energy stock attractive at the current price?
The data as of Nov 7, 2026: price ¥3.29, calculated fair value ¥0.5700 (−83%), Quality Score 40/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 300111 calculated?
We run Zhejiang Sunflower Light Energy through 2 models from 2 families: Multiples, Asset-Based. Every model gets the same audited fundamentals; the fair value of ¥0.5700 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Zhejiang Sunflower Light Energy itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Zhejiang Sunflower Light Energy (300111)?
The closing price on Nov 6, 2026 was ¥3.29. Our model-based fair value is ¥0.5700, about 83% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Zhejiang Sunflower Light Energy right now?
The price sits above even our optimistic bull case (¥0.6000). The favourable scenario is already priced in. Weak quality (40/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. The models converge in a tight band (¥0.5400 to ¥0.6000), unusually little disagreement for a valuation.
Where does the earnings growth of Zhejiang Sunflower Light Energy (300111) come from?
Earnings per share at Zhejiang Sunflower Light Energy grew −14.3 % a year from 2013 to 2024. Broken into its drivers: revenue per share −16.1 %, EBIT margin +5.3 %, tax rate +1.2 %, residual (interest, one-offs) −4.1 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Zhejiang Sunflower Light Energy

How large is the market capitalisation of Zhejiang Sunflower Light Energy (300111)?
The market capitalisation of Zhejiang Sunflower Light Energy is 4.2B CNY (≈ $635M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Zhejiang Sunflower Light Energy (300111)?
The price-to-sales ratio of Zhejiang Sunflower Light Energy is 17.1 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Zhejiang Sunflower Light Energy (300111)?
Earnings per share at Zhejiang Sunflower Light Energy are ¥−0.0100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Zhejiang Sunflower Light Energy (300111)?
The net margin of Zhejiang Sunflower Light Energy is −1.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Zhejiang Sunflower Light Energy (300111)?
The return on equity (ROE) of Zhejiang Sunflower Light Energy is −2.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Zhejiang Sunflower Light Energy (300111)?
On an EBIT basis the return on assets of Zhejiang Sunflower Light Energy is 2.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Zhejiang Sunflower Light Energy (300111)?
The operating margin of Zhejiang Sunflower Light Energy is 1.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Zhejiang Sunflower Light Energy (300111)?
Revenue at Zhejiang Sunflower Light Energy is growing −25.2% versus a year earlier (3y avg −6.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Zhejiang Sunflower Light Energy (300111)?
Earnings per share at Zhejiang Sunflower Light Energy are growing −94.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Zhejiang Sunflower Light Energy (300111) generate?
The free cash flow of Zhejiang Sunflower Light Energy is −5.6M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Zhejiang Sunflower Light Energy (300111) hold?
Zhejiang Sunflower Light Energy holds more cash than debt, 563M CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Zhejiang Sunflower Light Energy in the live analysis

One click puts Zhejiang Sunflower Light Energy on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.